Skip to content
FLFunding Landscape
Coming Soon·Opens soon·Synced from source July 6, 2026

Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)

National Institutes of Health

View official posting
Posted
Mar 4, 2026
Closes
No deadline published by the funder
Last verified
Jul 6, 2026

Classification and identifiers

Solicitation number
PAR-26-132
Assistance listing (CFDA)
93.866

Amount

Amount not published by the funder

Who can apply

Tribal organizationsHousing authoritiesSchool districtsTribal governmentsPublic universitiesNonprofits

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

About this opportunity

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on Alzheimer's disease (AD) and AD-related dementias (ADRD) drug target validation and early-stage drug discovery against novel targets. This NOFO will utilize the U01 activity code. The NOFO will support rigorous preclinical AD/ADRD drug target validation and early-stage drug discovery of small molecules, biologic, and emerging therapeutic modalities. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into AD/ADRD and drug discovery are encouraged to begin to consider applying for this ...

Related opportunities

Finding similar opportunities...